Nuvation Bio Inc. Class A Common Stock (NUVB)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Nuvation Bio as a Graham-style analyst: show me earnings, assets, and a margin of safety. The company is a clinical-stage biopharmaceutical firm with IBTROZI (taletrectinib) for ROS1+ non-small cell lung cancer and safusidenib in Phase 3 for IDH1-mutant astrocytoma. The financial record is early and erratic. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $83.2M and net income was $5.4M, or $0.01 per diluted share. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue fell to $31.7M and net loss was $62.8M, or -$0.18 per diluted share. For fiscal year 2025 ended 2025-12-31, revenue was $62.9M and net loss was $204.6M; for fiscal year 2024 ended 2024-12-31, revenue was $7.9M and net loss was $567.9M. So sales are appearing, but profits are not durable. At the 2026-10-13 close of $4.72, FairStock's P/E is -10.73 and P/B is 6.47; ROE is -47.81%, ROCE -12.36%, and FCF yield -7.8%. FairStock's Piotroski score is 2/9, Altman Z-Score is 0.67, and its composite score is 48/100, which suggests weak financial strength. The moat, if any, depends on clinical success and reimbursement, not on present financials. The bull case requires IBTROZI and safusidenib to become durable products. Until losses narrow and cash flow turns positive, this is speculation on science, not a proven business, and a margin of safety is not obvious at this price.

In plain English: Nuvation Bio is a biotechnology company developing cancer drugs, including a lung-cancer treatment and a brain-tumor treatment. The business is not yet consistently profitable: it is reporting some sales, but also large losses and negative cash flow. At the 2026-10-13 close of $4.72, the price looks expensive relative to its current profits and cash generation, so much of the value depends on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer